Articles by Leah Lawrence
Experts explore the impact of policy changes directed at the NIH to freeze research funds and terminate grants.
The FDA approvals of CAR T-cell therapies have changed the treatment landscape for several hematologic malignancies.
Blood Cancers Today spoke with several clinicians about how quadruplets are changing the myeloma treatment landscape.
According to a study, patients with MDS and CMML have dismal clinical outcomes after failure of HMA therapy.
Investigational combinations for MDS appeared to be well tolerated while triplets results in high-grade toxicity.
Phase 2 study results outline benefit of adding venetoclax to intensive chemo in MDS and AML patients.
The interest in using quantitative tests to measure residual cancer cells continues to expand in the arena of blood cancers.
While research on CHIP has gained momentum in recent years, treating the premalignant condition remains in debate.
Following FDA approval, luspatercept and imetelstat are propelling the MDS treatment landscape forward.
Benefits of CAR T-cell therapy outweigh the hypothetical future risk of secondary malignancies.
A new evaluation of the CLL-IPI revealed that its impact appears diminished in predicting OS in the era of targeted drugs.
The ELCLV3-21 high-risk signature distinguished those with MBL with a high probability of progression.
In single-cell resolved multi-omics analyses, T-bet expression in CLL cells correlated with longer overall patient survival.
Researchers are working to define and validate the ways in which mass spectrometry can aid in MM diagnosis and monitoring.
Shortages of essential drugs are not new, with one expert describing it as a “whack-a-mole” problem.
OS was still inversely proportional to the IPSS-M, but the molecular risk stratification had no additional prognostic power.
Here’s what they add to the treatment toolbox for hematologic malignancies.
Researchers and clinicians are attempting to make clinical trials better reflect the population of patients with MM.
Researchers presented updated data from the phase I XPORT-MF-034 trial at the Eleventh SOHO Annual Meeting.
The open-label ACE-536-MF-001 study included patient cohorts grouped by transfusion dependance and ruxolitinib therapy.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.